Autoimmune Addison disease is an endocrinopathy that is fatal if not diagnosed and treated in a timely manner. Its rarity has hampered unbiased studies of the predisposing genetic factors. A 2021 genome-wide association study, explaining up to 40% of the genetic susceptibility, has revealed new disease loci and reproduced some of the previously reported associations, while failing to reproduce others. Credible risk loci from both candidate gene and genome-wide studies indicate that, like one of its most common comorbidities, type 1 diabetes mellitus, Addison disease is primarily caused by aberrant T cell behaviour. Here, we review the current understanding of the genetics of autoimmune Addison disease and its position in the wider field of autoimmune disorders. The mechanisms that could underlie the effects on the adrenal cortex are also discussed.
Autoimmune Addison disease (AAD) is an oligogenic complex disease.
Genetic risk loci for AAD largely overlap with known autoimmune comorbidities.
In particular, HLA and autoimmune regulator (AIRE) variants predispose to AAD.
Probable functional elements of genetic risk variants highlight a T cell aetiology for AAD.
This is a preview of subscription content, access via your institution
Subscribe to Nature+
Get immediate online access to the entire Nature family of 50+ journals
Subscribe to Journal
Get full journal access for 1 year
only $8.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Addison, T. On the Constitutional and Local Effects of Disease of the Suprarenal Capsules (Highley, 1855). This is the first description of primary adrenal failure, including patients who probably had autoimmune disease.
Husebye, E. S. et al. Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency. J. Intern. Med. 275, 104–115 (2014).
Saverino, S. & Falorni, A. Autoimmune Addison’s disease. Best. Pract. Res. Clin. Endocrinol. Metab. 34, 101379 (2020).
Eriksson, D. et al. GWAS for autoimmune Addison’s disease identifies multiple risk loci and highlights AIRE in disease susceptibility. Nat. Commun. 12, 959 (2021). This study is the first unbiased genetic study of autoimmune Addison disease.
Erichsen, M. M. et al. Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry. J. Clin. Endocrinol. Metab. 94, 4882–4890 (2009).
del Pilar Larosa, M. et al. A new ELISA for autoantibodies to steroid 21-hydroxylase. Clin. Chem. Lab. Med. 56, 933–938 (2018).
Mitchell, A. L. & Pearce, S. H. Autoimmune Addison disease: pathophysiology and genetic complexity. Nat. Rev. Endocrinol. 8, 306–316 (2012).
Skov, J. et al. Heritability of Addison’s disease and prevalence of associated autoimmunity in a cohort of 112,100 Swedish twins. Endocrine 58, 521–527 (2017).
Skov, J. et al. Co-aggregation and heritability of organ-specific autoimmunity: a population-based twin study. Eur. J. Endocrinol. 182, 473–480 (2020).
Solomon, I. L. & Blizzard, R. M. Autoimmune disorders of endocrine glands. J. Pediatr. 63, 1021–1033 (1963).
Lettre, G. & Rioux, J. D. Autoimmune diseases: insights from genome-wide association studies. Hum. Mol. Genet. 17, R116–R121 (2008).
Eriksson, D. et al. Extended exome sequencing identifies BACH2 as a novel major risk locus for Addison’s disease. J. Intern. Med. 280, 595–608 (2016).
Myhre, A. G. et al. Autoimmune adrenocortical failure in Norway autoantibodies and human leukocyte antigen class II associations related to clinical features. J. Clin. Endocrinol. Metab. 87, 618–623 (2002).
Gambelunghe, G. et al. Microsatellite polymorphism of the MHC class I chain-related (MIC-A and MIC-B) genes marks the risk for autoimmune Addison’s disease. J. Clin. Endocrinol. Metab. 84, 3701–3707 (1999).
Park, Y. S. et al. Additional association of intra-MHC genes, MICA and D6S273, with Addison’s disease. Tissue Antigens 60, 155–163 (2002).
Kemp, E. H. et al. A cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism is associated with autoimmune Addison’s disease in English patients. Clin. Endocrinol. 49, 609–613 (1998).
Vaidya, B. et al. Association analysis of the cytotoxic T lymphocyte antigen-4 (CTLA-4) and autoimmune regulator-1 (AIRE-1) genes in sporadic autoimmune Addison’s disease. J. Clin. Endocrinol. Metab. 85, 688–691 (2000).
Blomhoff, A. et al. Polymorphisms in the cytotoxic T lymphocyte antigen-4 gene region confer susceptibility to Addison’s disease. J. Clin. Endocrinol. Metab. 89, 3474–3476 (2004).
Velaga, M. R. et al. The codon 620 tryptophan allele of the lymphoid tyrosine phosphatase (LYP) gene is a major determinant of Graves’ disease. J. Clin. Endocrinol. Metab. 89, 5862–5865 (2004).
Kahles, H. et al. Sex-specific association of PTPN22 1858T with type 1 diabetes but not with Hashimoto’s thyroiditis or Addison’s disease in the German population. Eur. J. Endocrinol. 153, 895–899 (2005).
Bottini, N. et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat. Genet. 36, 337–338 (2004).
Bronstad, I. et al. CYP21A2 polymorphisms in patients with autoimmune Addison’s disease, and linkage disequilibrium to HLA risk alleles. Eur. J. Endocrinol. 171, 743–750 (2014).
Brønstad, I., Wolff, A. S., Løvås, K., Knappskog, P. M. & Husebye, E. S. Genome-wide copy number variation (CNV) in patients with autoimmune Addison’s disease. BMC Med. Genet. 12, 111 (2011).
Eriksson, D. et al. Common genetic variation in the autoimmune regulator (AIRE) locus is associated with autoimmune Addison’s disease in Sweden. Sci. Rep. 8, 8395 (2018).
Lopez, E. R. et al. A promoter polymorphism of the CYP27B1 gene is associated with Addison’s disease, Hashimoto’s thyroiditis, Graves’ disease and type 1 diabetes mellitus in Germans. Eur. J. Endocrinol. 151, 193–197 (2004).
Mitchell, A. L. et al. Association of autoimmune Addison’s disease with alleles of STAT4 and GATA3 in European cohorts. PLoS ONE 9, e88991 (2014).
Jennings, C. E., Owen, C. J., Wilson, V. & Pearce, S. H. A haplotype of the CYP27B1 promoter is associated with autoimmune Addison’s disease but not with Graves’ disease in a UK population. J. Mol. Endocrinol. 34, 859–863 (2005).
Fichna, M. et al. Association of the CYP27B1 C(−1260)A polymorphism with autoimmune Addison’s disease. Exp. Clin. Endocrinol. Diabetes 118, 544–549 (2009).
Pani, M. A., Seissler, J., Usadel, K. H. & Badenhoop, K. Vitamin D receptor genotype is associated with Addison’s disease. Eur. J. Endocrinol. 147, 635–640 (2002).
Sakaue, S. et al. A cross-population atlas of genetic associations for 220 human phenotypes. Nat. Genet. 53, 1415–1424 (2021).
Onengut-Gumuscu, S. et al. Fine mapping of type 1 diabetes susceptibility loci and evidence for colocalization of causal variants with lymphoid gene enhancers. Nat. Genet. 47, 381–386 (2015).
International Multiple Sclerosis Genetics Consortium et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat. Genet. 45, 1353–1360 (2013).
Schmiedel, B. J. et al. Impact of genetic polymorphisms on human immune cell gene expression. Cell 175, 1701–1715.e16 (2018).
Buniello, A. et al. The NHGRI-EBI GWAS catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res. 47, D1005–D1012 (2019).
Wise, A. L., Gyi, L. & Manolio, T. A. eXclusion: toward integrating the X chromosome in genome-wide association analyses. Am. J. Hum. Genet. 92, 643–647 (2013).
Skinningsrud, B. et al. Multiple loci in the HLA complex are associated with Addison’s disease. J. Clin. Endocrinol. Metab. 96, E1703–E1708 (2011).
Skinningsrud, B. et al. Polymorphisms in CLEC16A and CIITA at 16p13 are associated with primary adrenal insufficiency. J. Clin. Endocrinol. Metab. 93, 3310–3317 (2008).
Frommer, L. & Kahaly, G. J. Type 1 diabetes and autoimmune thyroid disease–the genetic link. Front. Endocrinol. 12, 618213 (2021). This article is a review of autoimmune polyendocrine syndrome type 3 genetic risk loci, many of which are shared with isolated AAD and the closely clinically related autoimmune polyendocrine syndrome type 2.
Cotsapas, C. et al. Pervasive sharing of genetic effects in autoimmune disease. PLoS Genet. 7, e1002254 (2011).
Cotsapas, C. & Hafler, D. A. Immune-mediated disease genetics: the shared basis of pathogenesis. Trends Immunol. 34, 22–26 (2013). This study demonstrates the wider sharing of genetic risk in autoimmune diseases.
Shooshtari, P., Huang, H. & Cotsapas, C. Integrative genetic and epigenetic analysis uncovers regulatory mechanisms of autoimmune disease. Am. J. Hum. Genet. 101, 75–86 (2017).
Price, A. L., Spencer, C. C. & Donnelly, P. Progress and promise in understanding the genetic basis of common diseases. Proc. Biol. Sci. 282, 20151684 (2015).
Pers, T. H. et al. Biological interpretation of genome-wide association studies using predicted gene functions. Nat. Commun. 6, 5890 (2015).
Schaid, D. J., Chen, W. & Larson, N. B. From genome-wide associations to candidate causal variants by statistical fine-mapping. Nat. Rev. Genet. 19, 491–504 (2018).
Agarwala, V. et al. Evaluating empirical bounds on complex disease genetic architecture. Nat. Genet. 45, 1418–1427 (2013).
Bomba, L., Walter, K. & Soranzo, N. The impact of rare and low-frequency genetic variants in common disease. Genome Biol. 18, 77 (2017).
Skinningsrud, B. et al. Mutation screening of PTPN22: association of the 1858T-allele with Addison’s disease. Eur. J. Hum. Genet. 16, 977–982 (2008).
Roycroft, M. et al. The tryptophan 620 allele of the lymphoid tyrosine phosphatase (PTPN22) gene predisposes to autoimmune Addison’s disease. Clin. Endocrinol. 70, 358–362 (2009).
Tizaoui, K. et al. The role of PTPN22 in the pathogenesis of autoimmune diseases: a comprehensive review. Semin. Arthritis Rheum. 51, 513–522 (2021).
Maine, C. J. et al. PTPN22 alters the development of regulatory T cells in the thymus. J. Immunol. 188, 5267–5275 (2012).
Klocke, K., Sakaguchi, S., Holmdahl, R. & Wing, K. Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood. Proc. Natl Acad. Sci. USA 113, E2383–E2392 (2016).
Romo-Tena, J., Gómez-Martín, D. & Alcocer-Varela, J. CTLA-4 and autoimmunity: new insights into the dual regulator of tolerance. Autoimmun. Rev. 12, 1171–1176 (2013).
Walker, L. S. K. CTLA-4 and autoimmunity: new twists in the tale. Trends Immunol. 36, 760–762 (2015).
Shapiro, M. R. et al. De-coding genetic risk variants in type 1 diabetes. Immunol. Cell Biol. 99, 496–508 (2021).
Trynka, G. et al. Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease. Nat. Genet. 43, 1193–1201 (2011).
Jin, Y. et al. Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. N. Engl. J. Med. 362, 1686–1697 (2010).
Tang, X.-F. et al. Association analyses identify three susceptibility loci for vitiligo in the Chinese Han population. J. Invest. Dermatol. 133, 403–410 (2013).
Jin, Y. et al. Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants. Nat. Genet. 48, 1418–1424 (2016).
Dubois, P. C. et al. Multiple common variants for celiac disease influencing immune gene expression. Nat. Genet. 42, 295–302 (2010).
Hunt, K. A. et al. Newly identified genetic risk variants for celiac disease related to the immune response. Nat. Genet. 40, 395–402 (2008).
Schneider, C. et al. MicroRNA 28 controls cell proliferation and is down-regulated in B-cell lymphomas. Proc. Natl Acad. Sci. USA 111, 8185–8190 (2014).
Li, Q. et al. miR-28 modulates exhaustive differentiation of T cells through silencing programmed cell death-1 and regulating cytokine secretion. Oncotarget 7, 53735–53750 (2016).
Sharpe, A. H. & Pauken, K. E. The diverse functions of the PD1 inhibitory pathway. Nat. Rev. Immunol. 18, 153–167 (2018).
Mitchell, A. L. et al. Programmed death ligand 1 (PD-L1) gene variants contribute to autoimmune Addison’s disease and Graves’ disease susceptibility. J. Clin. Endocrinol. Metab. 94, 5139–5145 (2009).
Almeida, R. et al. Fine mapping of the celiac disease-associated LPP locus reveals a potential functional variant. Hum. Mol. Genet. 23, 2481–2489 (2014).
Sollid, L. M., Pos, W. & Wucherpfennig, K. W. Molecular mechanisms for contribution of MHC molecules to autoimmune diseases. Curr. Opin. Immunol. 31, 24–30 (2014).
Kraus, A. U. et al. HLA-DQB1 position 57 defines susceptibility to isolated and polyglandular autoimmunity in adults: interaction with gender. J. Clin. Endocrinol. Metab. 104, 1907–1916 (2019).
Dawoodji, A. et al. High frequency of cytolytic 21-hydroxylase-specific CD8+ T cells in autoimmune Addison’s disease patients. J. Immunol. 193, 2118–2126 (2014).
Roychoudhuri, R. et al. BACH2 represses effector programs to stabilize Treg-mediated immune homeostasis. Nature 498, 506–510 (2013).
Sidwell, T. & Kallies, A. Bach2 is required for B cell and T cell memory differentiation. Nat. Immunol. 17, 744–745 (2016).
Jang, E. et al. Bach2 deficiency leads autoreactive B cells to produce IgG autoantibodies and induce lupus through a T cell-dependent extrafollicular pathway. Exp. Mol. Med. 51, 1–13 (2019).
Zhang, H. et al. Bach2 deficiency leads to spontaneous expansion of IL-4-producing T follicular helper cells and autoimmunity. Front. Immunol. 10, 2050 (2019).
Sidwell, T. et al. Attenuation of TCR-induced transcription by Bach2 controls regulatory T cell differentiation and homeostasis. Nat. Commun. 11, 252 (2020).
Overacre, A. E. & Vignali, D. A. Treg stability: to be or not to be. Curr. Opin. Immunol. 39, 39–43 (2016).
Ohkura, N. et al. T cell receptor stimulation-induced epigenetic changes and Foxp3 expression are independent and complementary events required for Treg cell development. Immunity 37, 785–799 (2012).
The Australia and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene) Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat. Genet. 41, 824–828 (2009).
White, J. H. Vitamin D metabolism and signaling in the immune system. Rev. Endocr. Metab. Disord. 13, 21–29 (2012).
Szymczak, I. & Pawliczak, R. The active metabolite of vitamin D3 as a potential immunomodulator. Scand. J. Immunol. 83, 83–91 (2016).
Devallière, J. & Charreau, B. The adaptor Lnk (SH2B3): an emerging regulator in vascular cells and a link between immune and inflammatory signaling. Biochem. Pharmacol. 82, 1391–1402 (2011).
Törn, C. et al. Role of type 1 diabetes-associated SNPs on risk of autoantibody positivity in the TEDDY study. Diabetes 64, 1818–1829 (2015).
Ghaderi, M. et al. MHC2TA single nucleotide polymorphism and genetic risk for autoimmune adrenal insufficiency. J. Clin. Endocrinol. Metab. 91, 4107–4111 (2006).
Devaiah, B. N. & Singer, D. S. CIITA and its dual roles in MHC gene transcription. Front. Immunol. 4, 476 (2013).
Hain, H. S. et al. Inducible knockout of Clec16a in mice results in sensory neurodegeneration. Sci. Rep. 11, 9319 (2021).
Pearson, G. et al. Clec16a, Nrdp1, and USP8 form a ubiquitin-dependent tripartite complex that regulates β-cell mitophagy. Diabetes 67, 265–277 (2018).
Pandey, R. et al. CLEC16A regulates splenocyte and NK cell function in part through MEK signaling. PLoS ONE 13, e0203952 (2018).
Hellesen, A. & Bratland, E. The potential role for infections in the pathogenesis of autoimmune Addison’s disease: infections and autoimmune Addison’s disease. Clin. Exp. Immunol. 195, 52–63 (2019).
Rijvers, L. et al. The role of autoimmunity-related gene CLEC16A in the B cell receptor-mediated HLA class II pathway. J. Immunol. 205, 945–956 (2020).
Schuster, C. et al. The autoimmunity-associated gene CLEC16A modulates thymic epithelial cell autophagy and alters T cell selection. Immunity 42, 942–952 (2015).
Stahl, E. A. et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat. Genet. 42, 508–514 (2010).
Fathman, J. W. et al. NIP45 controls the magnitude of the type 2 T helper cell response. Proc. Natl Acad. Sci. USA 107, 3663–3668 (2010).
Zemmour, D., Pratama, A., Loughhead, S. M., Mathis, D. & Benoist, C. Flicr, a long noncoding RNA, modulates Foxp3 expression and autoimmunity. Proc. Natl Acad. Sci. USA 114, E3472–E3480 (2017).
Brajic, A. et al. The long non-coding RNA flatr anticipates Foxp3 expression in regulatory T cells. Front. Immunol. 9, 1989 (2018).
Van Gorp, H., Kuchmiy, A., Van Hauwermeiren, F. & Lamkanfi, M. NOD-like receptors interfacing the immune and reproductive systems. FEBS J. 281, 4568–4582 (2014).
Costa, F. R. C. et al. NLRP1 acts as a negative regulator of Th17 cell programming in mice and humans with autoimmune diabetes. Cell Rep. 35, 109176 (2021).
Bärenwaldt, A. & Läubli, H. The sialoglycan-Siglec glyco-immune checkpoint–a target for improving innate and adaptive anti-cancer immunity. Expert Opin. Ther. Targets 23, 839–853 (2019).
van de Wall, S., Santegoets, K. C. M., van Houtum, E. J. H., Büll, C. & Adema, G. J. Sialoglycans and siglecs can shape the tumor immune microenvironment. Trends Immunol. 41, 274–285 (2020).
Stanczak, M. A. et al. Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells. J. Clin. Invest. 128, 4912–4923 (2018).
Ban, M. et al. Transcript specific regulation of expression influences susceptibility to multiple sclerosis. Eur. J. Hum. Genet. 28, 826–834 (2020).
Brdičková, N. et al. LIME: a new membrane Raft-associated adaptor protein involved in CD4 and CD8 coreceptor signaling. J. Exp. Med. 198, 1453–1462 (2003).
Son, M. et al. LIME mediates immunological synapse formation through activation of VAV. Mol. Cell 33, 407–414 (2012).
Ge, Y., Paisie, T. K., Chen, S. & Concannon, P. UBASH3A regulates the synthesis and dynamics of TCR–CD3 complexes. J. Immunol. 203, 2827–2836 (2019).
Todd, J. A. Evidence that UBASH3 is a causal gene for type 1 diabetes. Eur. J. Hum. Genet. 26, 925–927 (2018).
Husebye, E. S., Anderson, M. S. & Kampe, O. Autoimmune polyendocrine syndromes. N. Engl. J. Med. 378, 1132–1141 (2018).
Chiou, J. et al. Interpreting type 1 diabetes risk with genetics and single-cell epigenomics. Nature 594, 398–402 (2021).
Laisk, T. et al. Genome-wide association study identifies five risk loci for pernicious anemia. Nat. Commun. 12, 3761 (2021).
Sadeghian-Rizi, T., Alsahebfosoul, F., Kazemi, M., Khanahmad, H. & Jahanian-Najafabadi, A. Association of AIRE polymorphism and the susceptibility to multiple sclerosis in Iranian population. Avicenna J. Med. Biotechnol. 10, 110–114 (2018).
Bruserud, O., Oftedal, B. E., Wolff, A. B. & Husebye, E. S. AIRE-mutations and autoimmune disease. Curr. Opin. Immunol. 43, 8–15 (2016).
Henze, L., Schwinge, D. & Schramm, C. The effects of androgens on T cells: clues to female predominance in autoimmune liver diseases? Front. Immunol. 11, 1567 (2020).
Zhu, M.-L. et al. Sex bias in CNS autoimmune disease mediated by androgen control of autoimmune regulator. Nat. Commun. 7, 11350 (2016).
Boag, A. M. & Catchpole, B. A review of the genetics of hypoadrenocorticism. Top. Companion Anim. Med. 29, 96–101 (2014).
Oberbauer, A., Bell, J., Belanger, J. & Famula, T. Genetic evaluation of Addison’s disease in the Portuguese Water Dog. BMC Vet. Res. 2, 15 (2006).
Treeful, A. E., Rendahl, A. K. & Friedenberg, S. G. DLA class II haplotypes show sex-specific associations with primary hypoadrenocorticism in Standard Poodle dogs. Immunogenetics 71, 373–382 (2019).
Gershony, L. C. et al. DLA class II risk haplotypes for autoimmune diseases in the bearded collie offer insight to autoimmunity signatures across dog breeds. Canine Genet. Epidemiol. 6, 2 (2019).
Boag, A. M. et al. Polymorphisms in the CTLA4 promoter sequence are associated with canine hypoadrenocorticism. Canine Med. Genet. 7, 2 (2020).
Gershony, L. C. et al. Genetic characterization of Addison’s disease in Bearded Collies. BMC Genomics 21, 833 (2020).
Liu, Y., Yin, H., Zhao, M. & Lu, Q. TLR2 and TLR4 in autoimmune diseases: a comprehensive review. Clin. Rev. Allergy Immunol. 47, 136–147 (2014).
Aslaksen, S. et al. Identification and characterization of rare toll-like receptor 3 variants in patients with autoimmune Addison’s disease. J. Transl. Autoimmun. 1, 100005 (2019).
Boag, A. M. et al. A longitudinal study of autoantibodies against cytochrome P450 side-chain cleavage enzyme in dogs (Canis lupus familiaris) affected with hypoadrenocorticism (Addison’s disease). Vet. Immunol. Immunopathol. 202, 41–45 (2018).
Treeful, A. & Friedenberg, S. Identifying autoantibody biomarkers for Addison’s disease in dogs. J. Immunol. 204, 92.25 (2020).
Maher, B. Personal genomes: the case of the missing heritability. Nature 456, 18–21 (2008).
Young, A. I. Solving the missing heritability problem. PLoS Genet. 15, e1008222 (2019).
Douglas, G. M., Bielawski, J. P. & Langille, M. G. I. Re-evaluating the relationship between missing heritability and the microbiome. Microbiome 8, 87 (2020).
Tam, V. et al. Benefits and limitations of genome-wide association studies. Nat. Rev. Genet. 20, 467–484 (2019).
Dalin, F. et al. Clinical and immunological characteristics of autoimmune Addison disease: a nationwide Swedish multicenter study. J. Clin. Endocrinol. Metab. 102, 379–389 (2017).
Bjoro, T. et al. Prevalence of thyroid disease, thyroid dysfunction and thyroid peroxidase antibodies in a large, unselected population. The Health Study of Nord-Trondelag (HUNT). Eur. J. Endocrinol. 143, 639–647 (2000).
Naletto, L. et al. The natural history of autoimmune Addison’s disease from the detection of autoantibodies to development of the disease: a long follow-up study on 143 patients. Eur. J. Endocrinol. 180, 223–234 (2019).
Sævik, Å. B. et al. Residual corticosteroid production in autoimmune Addison disease. J. Clin. Endocrinol. Metab. 105, 2430–2441 (2020).
Napier, C. et al. Residual adrenal function in autoimmune Addison’s disease–effect of dual therapy with rituximab and depot tetracosactide. J. Clin. Endocrinol. Metab. 105, e1250–e1259 (2020).
Owen, C. J. et al. Analysis of the Fc receptor-like-3 (FCRL3) locus in Caucasians with autoimmune disorders suggests a complex pattern of disease association. J. Clin. Endocrinol. Metab. 92, 1106–1111 (2007).
Mitchell, A. L. et al. Linkage analysis in autoimmune Addison’s disease: NFATC1 as a potential novel susceptibility locus. PLoS ONE 10, e0123550 (2015).
Wolff, A. S. et al. CTLA-4 as a genetic determinant in autoimmune Addison’s disease. Genes. Immun. 16, 430–436 (2015).
Fichna, M. et al. Interleukin-2 and subunit alpha of its soluble receptor in autoimmune Addison’s disease–an association study and expression analysis. Autoimmunity 48, 100–107 (2015).
Gombos, Z. et al. Analysis of extended human leukocyte antigen haplotype association with Addison’s disease in three populations. Eur. J. Endocrinol. 157, 757–761 (2007). This study identified multi-population HLA haplotype associations with AAD.
Maclaren, N. K. & Riley, W. J. Inherited susceptibility to autoimmune Addison’s disease is linked to human leukocyte antigens-DR3 and/or DR4, except when associated with type I autoimmune polyglandular syndrome. J. Clin. Endocrinol. Metab. 62, 455–459 (1986). This is the earliest genetic study of AAD.
Pazderska, A. et al. A variant in the BACH2 gene is associated with susceptibility to autoimmune Addison’s disease in humans. J. Clin. Endocrinol. Metab. 101, 3865–3869 (2016).
Fichna, M. et al. Polymorphism in BACH2 gene is a marker of polyglandular autoimmunity. Endocrine 74, 72–79 (2021).
Magitta, N. F. et al. A coding polymorphism in NALP1 confers risk for autoimmune Addison’s disease and type 1 diabetes. Genes. Immun. 10, 120–124 (2009).
Zurawek, M. et al. A coding variant in NLRP1 is associated with autoimmune Addison’s disease. Hum. Immunol. 71, 530–534 (2010).
Napier, C., Mitchell, A. L., Gan, E., Wilson, I. & Pearce, S. H. Role of the X-linked gene GPR174 in autoimmune Addison’s disease. J. Clin. Endocrinol. Metab. 100, E187–E190 (2015).
The authors declare no competing interests.
Peer review information
Nature Reviews Endocrinology thanks the anonymous reviewers for their contribution to the peer review of this work.
- Linkage disequilibrium
Allelic states at separate genetic loci being correlated beyond what is predicted by their respective frequencies.
- Expression quantitative trait loci
(eQTL). Loci at which variants affect the expression of one or more genes.
- Suggestive significance level
Defined here as P < 1e−5, P values below which a genetic association signal investigation is warranted despite not reaching the commonly used genome-wide significance threshold.
- Genome-wide significance level
P < 5e−8, the P value threshold for statistical significance, based on the estimated number of common, independent single nucleotide polymorphisms in the human genome.
- Background range
Defined here heuristically as within the indistinguishable mass of high P values in a Manhattan plot; in the current case 0.01 or larger.
- Prioritized gene
Defined here as the gene predicted to be the causative element of any given association signal.
About this article
Cite this article
Røyrvik, E.C., Husebye, E.S. The genetics of autoimmune Addison disease: past, present and future. Nat Rev Endocrinol 18, 399–412 (2022). https://doi.org/10.1038/s41574-022-00653-y